HROW · Harrow, Inc.

Current Thesis

Harrow's second-half revenue-ramp thesis has failed its published price test; the Q3 results remain the test of whether the operating recovery can support a new case. The 2026-09-18 adjusted close of $33.08 is below the $36 weekly-close invalidation published on 2026-09-05. That condition has occurred, rather than remaining a prospective risk.

The operating proposition remains identifiable. Harrow reaffirmed FY2026 revenue guidance of $350–365 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $80–100 million on 2026-08-10. In the accompanying shareholder letter, management explicitly acknowledged that its guidance requires second-half revenue exceeding twice first-half revenue. That is management's expectation, not a measured recovery. Q2 shareholder letter

For the previously published setup, the narrative is dead — the 2026-09-18 weekly close broke its stated price condition despite Leerink Partners initiating Outperform coverage with a $45 analyst target on 2026-09-09. This is an inference about the failed market structure, not a finding that Harrow's products have failed commercially. Leerink initiation

Bullish and bearish views on Harrow, Inc.

The model's bull view on Harrow, Inc. (HROW), in brief: Branded demand provides operating evidence. The bear view: The published price condition failed. The 2026-09-18 adjusted close of $33.08 breached the $36 weekly threshold identified in the 2026-09-05 dossier. Lowering that threshold would change the original test after its outcome. Revenue missed management's quarterly floor. The… Both cases follow in full.

Bull Case

• Branded demand provides operating evidence. Harrow's 2026-08-10 release reported Q2 VEVYE revenue of $29.4 million, up approximately 58% year over year, and IHEEZO unit demand up 44% sequentially. The recovery interpretation would weaken if the Q3 release shows those gains failing to translate into higher consolidated revenue. Q2 results
• Coverage expansion supports the ramp. The 2026-08-10 release identified expanded VEVYE formulary coverage effective 2026-08-01 with a major commercial pharmacy benefit manager. Management's expectation of a greater commercial prescription mix remains unconfirmed; a subsequent disclosure of unchanged or declining commercial mix would contradict that mechanism. Q2 results
• New analyst coverage remains constructive. Leerink's 2026-09-09 initiation assigned Outperform and a $45 target. This documents a third party's favorable assessment; it does not establish incremental demand for the shares or validate the annual guidance. Analyst action

Bear Case

• The published price condition failed. The 2026-09-18 adjusted close of $33.08 breached the $36 weekly threshold identified in the 2026-09-05 dossier. Lowering that threshold would change the original test after its outcome.
• Revenue missed management's quarterly floor. The 2026-08-10 results reported Q2 revenue of $70.661 million against the previously announced $71–81 million range. The same release reported negative adjusted EBITDA of $1.2 million, while reaffirming the positive FY2026 range. A subsequent guidance reduction would establish a separate fundamental failure.
• Cash requirements remain material. The 2026-06-30 balance sheet reported $83.9 million of cash and $292.4 million of loans payable net. The TYRVAYA agreement dated 2026-08-03 requires $30 million at closing; these historical figures do not establish available cash on 2026-09-19. An offering or new borrowing explicitly linked to the acquisition would confirm additional financing requirements.

Setup & Price Structure

The supplied adjusted daily-bar series records a $33.08 close on 2026-09-18, a three-month price decline of 22.0%, and a 14-day relative strength index (RSI) of 28.6. These are measured observations. The momentum reading alone does not establish a reversal, and the available record does not establish a replacement support level below the breached $36 threshold.

Coverage has expanded while the published structure has failed. StockAnalysis's September 2026 recommendation table lists nine Strong Buy ratings, compared with eight in August; its dated action table includes Leerink's 2026-09-09 initiation. This is evidence of favorable analyst clustering, not evidence of crowded ownership. Current retail-flow, short-interest and moving-average measurements are missing, so no positioning verdict follows. Recommendation table

A disclosure omitted from the previous discussion also merits precision: Harrow's 2026-09-04 filing says Randall Pollard ceased serving as chief accounting officer and Andrew Boll assumed the principal accounting officer duties. The filing does not state a reason for the departure. September 4 Form 8-K

Catalyst Calendar (next 30 days)

• 2026-09-19 through 2026-10-19: No company-confirmed event within this window was identified on the investor calendar reviewed on 2026-09-19. The scheduled 2026-09-09, 2026-09-10 and 2026-09-15 conference dates have elapsed; their passage does not establish that guidance was reaffirmed during the discussions. Company calendar, September conference announcement
• ~2026-11-09, est.: The previously published estimate for Q3 results remains unconfirmed by the company calendar reviewed on 2026-09-19. This later release matters because it reports the first quarter of the second-half ramp underlying management's 2026-08-10 annual guidance. The estimate is not a scheduled company event. Company calendar

What Would Change Our Mind

The loss of the published stabilization level has already ended the original setup: a weekly close below $36 was the condition, and the 2026-09-18 close was $33.08. A subsequent recovery above $36 would constitute new evidence without reversing that recorded failure.

A renewed operating case would require the Q3 release to show revenue above Q2's $70.661 million and positive adjusted EBITDA while retaining the FY2026 guidance announced on 2026-08-10. Even that combination would support reassessment rather than prove delivery of the annual ranges. A reduction below the $350 million revenue floor or $80 million adjusted EBITDA floor would invalidate the corresponding guidance-recovery proposition.

Correlation Notes

This remains a single-company execution case: the dated evidence concerns Harrow's 2026-08-10 guidance, product demand and acquisition commitments. No matched peer-return series is available to establish that the 22.0% three-month decline through 2026-09-18 reflects a broader ophthalmology or biotechnology move. The evidence is insufficient to claim a sector correlation or group-driven recovery.